Advances in Clinical Pharmacology in Lung Cancer—2nd Edition

Dear Colleagues,

We are excited to launch the second edition of this Special Issue on the topic of advances in clinical pharmacology in lung cancer (https://www.mdpi.com/journal/cancers/special_issues/2KVP0U08G8).

Lung cancer has always been the deadliest cancer worldwide, largely due to being difficult to detect, meaning that it is often only discovered in its advanced stages. Since the development of EGFR TKI-targeted therapy, precision medicine has been increasingly implemented in lung cancer. With the integration of next-generation sequencing (NGS) technologies, various driver genes have been validated through clinical trials and real-world data, showing significant improvements in patient response rates, disease progression-free periods, and even survival rates compared to traditional chemotherapy. Beyond targeted therapies, the combined use of anti-angiogenesis drugs and the development of immunotherapy have set milestones in lung cancer treatment. These advances apply not only to systemic treatments in stage four lung cancer but also to earlier-stage lung cancer, where patients can receive them as neoadjuvant or adjuvant therapy, offering hope regarding long-term survival. In this Special Issue, we will further explore and discuss the pharmacological aspects and applications of these drugs, with the aim of contributing to advancing the treatment of lung cancer.

Prof. Dr. Chih-Jen Yang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.